TABLE 3

Drug X clearance values used in various scenarios

Drug XDosing RegimenτCLm0aCLPDbCLp0CLf0CLMPCLPM
l/h
Figure 2, a and bWeek 40, 16.7 mg/h continuous i.v. infusionN/A4.5 vs. 451.80000
Figure 2, c and dWeek 40, 400 mg single oral doseN/A4.5 vs. 451.80000
Figure 2, e and fWeek 40, 133.3-mg multiple oral doses8 h4.5 vs. 451.80000
Figure 2, g and hWeek 40, 400-mg multiple oral doses24 h4.5 vs. 451.80000
Figure 4, a and bWeek 40, 16.7 mg/h continuous i.v. infusionN/A451.8 vs. 180000
Figure 4, c and dWeek 40, 400-mg single oral doseN/A451.8 vs. 180000
Figure 4, e and fWeek 40, 400-mg multiple oral doses24 h451.8 vs. 180000
Figure 6aWeek 40, 400-mg single oral doseN/A451.80, 0.18, 0.90, 1.8000
Figure 6b00, 0.18, 0.9, 1.800
Figure 6c0, 0.18, 0.9, 1.80, 0.18, 0.9, 1.800
Figure 6d000, 0.18, 0.9, 1.80
Figure 6e0000, 0.18, 0.9, 1.8
Figure 8, a and b (scenario 1)400-mg single oral doseWeek 20N/A440.210000
Week 40451.80000
Figure 8, c and d (scenario 2)Week 20440.2100.1100
Week 40451.800.9000
Figure 8, e and f (scenario 3)Week 20440.210000.70
Week 40451.80000.36
Figure 8, g and h (scenario 4)Week 20440.2100.1100.70
Week 40451.800.9000.36
  • N/A, not applicable; week, gestational week.

  • a At 40 weeks, CLm0 was set at 45 l/h based on the published didanosine clearance value (see Supplemental Table 1; rounded down to the nearest integer).

  • b CLPD was extrapolated from the reported didanosine transplacental passive diffusion clearance in pregnant macaques based on body weight (for details, see Supplemental Table 1).